Wedbush Equities Analysts Raise Earnings Estimates for FHTX

Key Points

• Wedbush has increased its earnings estimates for Foghorn Therapeutics, predicting a Q3 2025 EPS of ($0.29), up from a previous estimate of ($0.33).
• Foghorn Therapeutics recently reported an EPS of ($0.28), which exceeded the consensus estimate of ($0.31), while revenue was $7.56 million, slightly below expectations.
• The company's stock has a current market cap of $273.13 million, with an average rating of "Buy" from analysts and a price target of $12.13.

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Stock analysts at Wedbush upped their Q3 2025 earnings per share estimates for Foghorn Therapeutics in a research note issued to investors on Tuesday, August 5th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.29) per share for the quarter, up from their previous forecast of ($0.33). The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. Wedbush also issued estimates for Foghorn Therapeutics' Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at $0.62 EPS.

Several other brokerages have also recently issued reports on FHTX. Citizens Jmp began coverage on Foghorn Therapeutics in a research report on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $9.00 target price on the stock. Citigroup began coverage on Foghorn Therapeutics in a research report on Wednesday, April 23rd. They issued an "outperform" rating on the stock. HC Wainwright raised Foghorn Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Finally, JMP Securities reissued a "market outperform" rating and issued a $9.00 target price on shares of Foghorn Therapeutics in a research report on Thursday, May 15th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $12.00.

Foghorn Therapeutics Stock Performance

Shares of NASDAQ:FHTX traded up $0.14 during midday trading on Thursday, reaching $4.72. 27,304 shares of the company's stock traded hands, compared to its average volume of 130,997. The company has a market cap of $266.82 million, a price-to-earnings ratio of -3.97 and a beta of 3.05. Foghorn Therapeutics has a one year low of $2.94 and a one year high of $10.25. The stock has a 50 day moving average of $5.13 and a 200 day moving average of $4.59.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. The business had revenue of $7.56 million for the quarter, compared to the consensus estimate of $7.62 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in FHTX. Point72 Asset Management L.P. raised its stake in shares of Foghorn Therapeutics by 58.8% in the fourth quarter. Point72 Asset Management L.P. now owns 634,761 shares of the company's stock worth $2,996,000 after buying an additional 235,059 shares during the period. Deerfield Management Company L.P. Series C raised its stake in Foghorn Therapeutics by 7.5% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 3,255,514 shares of the company's stock valued at $15,366,000 after purchasing an additional 227,628 shares during the period. Raymond James Financial Inc. raised its stake in Foghorn Therapeutics by 9.3% during the 1st quarter. Raymond James Financial Inc. now owns 2,218,352 shares of the company's stock valued at $8,097,000 after purchasing an additional 188,969 shares during the period. DAFNA Capital Management LLC raised its stake in Foghorn Therapeutics by 395.7% during the 4th quarter. DAFNA Capital Management LLC now owns 186,717 shares of the company's stock valued at $881,000 after purchasing an additional 149,053 shares during the period. Finally, Geode Capital Management LLC raised its stake in Foghorn Therapeutics by 16.9% during the 2nd quarter. Geode Capital Management LLC now owns 807,674 shares of the company's stock valued at $3,797,000 after purchasing an additional 116,979 shares during the period. Institutional investors own 61.55% of the company's stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.